Company profile: Neural Therapeutics
1.1 - Company Overview
Company description
- Provider of ethnobotanical drug discovery, psychedelic-based therapeutics for mental health, and dietary supplements. Focuses on San Pedro cactus for mescaline-derived compounds, conducts pharma and nutraceutical R&D leveraging indigenous knowledge, develops IP with partners like Validity Labs, and establishes sustainable, legally compliant sourcing and cultivation in Peru.
Products and services
- Ethnobotanical Drug Discovery: Neural Therapeutics architects drug discovery from psychoactive plants, with mescaline-focused research on the San Pedro cactus, advancing development pathways for plant-derived psychedelic therapeutics
- Psychedelic-based Therapeutics: Neural Therapeutics develops medical therapeutics derived from psychedelic compounds to address mental health conditions, employing an ethnobotanical, psychedelic-based approach grounded in psychoactive plant research
- Nutraceutical Products: Neural Therapeutics engineers dietary supplements derived from psychoactive plants, producing zero-waste formulations by utilizing the entire plant for nutraceutical applications and sustainable resource use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neural Therapeutics
RemeGenix
HQ: United States
Website
- Description: Provider of development stage biotechnology focused on the commercialization of disease-altering therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RemeGenix company profile →
Mission Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule therapeutics targeting deubiquitylating enzymes to enhance mitophagy and remove dysfunctional mitochondria for the treatment of cancer, acute kidney injury, and other diseases. Offerings include MTX325 (CNS-penetrant USP30 inhibitor), MTX652 (peripheral USP30 inhibitor), a proprietary DUB platform, and USP30 inhibitor programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mission Therapeutics company profile →
Amylyx Pharmaceuticals
HQ: United States
Website
- Description: Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amylyx Pharmaceuticals company profile →
CNS Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain; develops and markets safe, high-quality pharmaceuticals, including its first FDA-approved product, Gablofen. Based in St. Paul, Minn.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CNS Therapeutics company profile →
Balt
HQ: France
Website
- Description: Provider of interventional neuroradiology (INR) devices for treating strokes, aneurysms, and arteriovenous malformations. BALT designs, manufactures, and distributes essential devices such as catheters, stents, and coils, working with neurovascular surgeons to address complex, life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Balt company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neural Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neural Therapeutics
2.2 - Growth funds investing in similar companies to Neural Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neural Therapeutics
4.2 - Public trading comparable groups for Neural Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →